ReviewBrain communications2025
Can brain network connectivity facilitate the clinical development of disease-modifying anti-Alzheimer drugs?
Review in Brain communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- rTMS modulates early AD progression via synergistic brain network reorganization and peripheral biomarker dynamics.GeroScience · 2026Trial
- Neuroinflammatory and molecular pathways in Alzheimer's disease: mechanistic crosstalk and emerging therapeutic opportunities.Inflammopharmacology · 2026Review
- Neural networks and econometric models: Advancing brain connectivity for Alzheimer's drug development.Neural regeneration research · 2026Article
- Decreased amyloid-related structure-function coupling in preclinical Alzheimer's disease.Communications medicine · 2026Article
- Modeling Alzheimer's disease through the integration of exposome, inflammasome, and connectome.Neural regeneration research · 2026Article
- Do Anti-Amyloid Antibodies Modulate Brain Function in Alzheimer's Disease?Neuro-degenerative diseases · 2026Article
- Resting-state functional connectivity alterations after mild COVID-19 infection.BMC infectious diseases · 2025Article
- Brain Connectivity Gradients Alterations in Discordant Cerebrospinal Fluid Profile for Alzheimer's Disease Biomarkers.Human brain mapping · 2025Article
- State-Guided ICA of Functional Network Connectivity Reveals Temporal Signatures of Alzheimer's Disease.medRxiv : the preprint server for health sciences · 2025Article
- Complex non-Markovian dynamics and the dual role of astrocytes in Alzheimer's disease development and propagation.Quantitative biology (Beijing, China) · 2025Article
- Rethinking biological biomarkers to track treatment efficacy in Alzheimer's disease: Focus on brain connectivity.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Sleep on it!Brain communications · 2025Article
- Functional connectome metrics reveal distinct prognostic subtypes in two Phase 3 gantenerumab trials.Alzheimer's & dementia (New York, N. Y.)Article
- Brain network analysis in Alzheimer's disease and mild cognitive impairment using high-density diffuse optical tomography.Imaging neuroscience (Cambridge, Mass.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The preclinical phase of Alzheimer's disease represents a crucial time window for therapeutic intervention but requires the identification of clinically relevant biomarkers that are sensitive to the effects of disease-modifying drugs. Amyloid peptide and tau proteins, the main histological hallmarks of Alzheimer's disease, have been widely used as biomarkers of anti-amyloid and anti-tau drugs. However, these biomarkers do not fully capture the multiple biological pathways of the brain. Indeed, robust amyloid-target engagement by anti-amyloid monoclonal antibodies has recently translated into modest cognitive and clinical benefits in Alzheimer's disease patients, albeit with potentially life-threatening side effects. Moreover, targeting the tau pathway has yet to result in any positive clinical outcomes. Findings from computational neuroscience have demonstrated that brain regions do not work in isolation but are interconnected within complex network structures. Brain connectivity studies suggest that misfolded proteins can spread through these connections, leading to the hypothesis that Alzheimer's disease is a pathology of network disconnectivity. Based on these assumptions, here we discuss how incorporating brain connectivity outcomes could better capture global brain functionality and, in conjunction with traditional Alzheimer's disease biomarkers, could facilitate the clinical development of new disease-modifying anti-Alzheimer's disease drugs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.